GlassScriptPhysician profile
Geoffrey J Bisignani
NPI 1346345980
$14,887.84
in general payments reported to CMS, 2019-2025
42 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $2,329 · 2021: $930 · 2022: $1,906 · 2023: $6,281 · 2024: $1,457 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,900 · Food and Beverage: $3,840 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,900.00 |
| Food and Beverage | $3,839.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $3,664.00 | 2019-2025 | Xtandi, Myrbetriq |
| Boston Scientific Corporation | $2,502.83 | 2019-2023 | Lumenis Pulse 120h |
| Astrazeneca Pharmaceuticals LP | $1,836.75 | 2020-2025 | Lynparza |
| Sumitomo Pharma America, INC. | $1,137.56 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $1,004.42 | 2019-2025 | |
| Janssen Biotech, INC. | $858.97 | 2019-2025 | Erleada, Akeega |
| Pfizer INC. | $650.05 | 2019-2025 | |
| Myovant Sciences INC. | $539.53 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $388.75 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $261.84 | 2020-2025 | Prolaris |
| Tolmar, INC. | $261.61 | 2023-2025 | Eligard, Jatenzo |
| Procept Biorobotics Corporation | $167.09 | 2024-2025 | Aquabeam System |
| Merck Sharp & Dohme LLC | $162.93 | 2020-2025 | Keytruda, Welireg |
| Cumberland Pharmaceuticals, INC. | $155.41 | 2019-2025 | Caldolor |
| Tolmar Pharmaceuticals, INC. | $127.82 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Bisignani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.